Tioguanine
- Generic Name
- Tioguanine
- Brand Names
- Lanvis, Tabloid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N5S
- CAS Number
- 154-42-7
- Unique Ingredient Identifier
- WIX31ZPX66
- Background
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
- Indication
For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
- Associated Conditions
- Acute Non-Lymphocytic Leukemia, Nonlymphocytic Acute myeloid leukemia
- Associated Therapies
- -
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00866749
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: daunorubicin hydrochlorideDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: mercaptopurineDrug: thioguanineDrug: etoposideDrug: vincristine sulfateDrug: ifosfamideDrug: leucovorin calciumDrug: prednisoneDrug: vindesine
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- University Hospital, Motol
- Target Recruit Count
- 4000
- Registration Number
- NCT00764907
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czech Republic
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Calaspargase Pegol-mknlDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoneRadiation: Radiation TherapyDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 166
- Registration Number
- NCT00671034
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸University of Connecticut, Farmington, Connecticut, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2015-01-14
- Target Recruit Count
- 2039
- Registration Number
- NCT00613457
Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)
- Conditions
- Interventions
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00587873
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
- Conditions
- Interventions
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00588536
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 318
- Registration Number
- NCT00558519
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
- Conditions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 445
- Registration Number
- NCT00550992
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czechia
🇫🇷CHR Hotel Dieu, Nantes, France
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT00504660
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2021-03-17
- Target Recruit Count
- 9
- Registration Number
- NCT00439296
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.